Femoropopliteal Occlusive Disease

37.1Start with the limb problem

Femoropopliteal occlusive disease should first be framed by the patient’s limb problem, not by the device cabinet. In functionally limiting claudication, revascularization is generally a second-line strategy after medical therapy and structured exercise have failed to provide acceptable symptom control. This is especially important in the femoropopliteal segment because the durability of intervention is less predictable than in aortoiliac inflow disease, even though selected patients with femoropopliteal outflow disease may still benefit meaningfully from revascularization. ACC/AHA 2024

The practical bedside question in claudication is whether the patient’s walking limitation is severe enough, persistent enough, and anatomically suitable enough to justify accepting restenosis and reintervention risk. Contemporary guideline framing separates aortoiliac and femoropopliteal expectations: shorter femoropopliteal stenoses or occlusions are generally suited to an endovascular-first approach, whereas longer femoropopliteal lesions may achieve better long-term patency with surgical bypass when the patient is fit and suitable vein is available. ESC 2017

The surgeon should resist treating the angiogram in isolation. A short superficial femoral artery lesion in a disabled claudicant who has failed structured exercise is a different clinical problem from a long occlusion in a patient with tolerable symptoms. The former may justify endovascular treatment; the latter often requires a frank discussion that technical success may not equal durable functional success, and that bypass durability must be balanced against operative burden. ACC/AHA 2024 · ESC 2017

Device selection should follow lesion behavior and expected failure mode. For focal disease, balloon-based therapy, drug-coated technology, or stenting may be considered within the limits of trial evidence. For mechanically demanding superficial femoral or proximal popliteal segments, stent performance matters: in the SUPERB single-arm IDE experience, an interwoven nitinol stent achieved high 12-month patency, no core-lab-confirmed fractures among evaluated stents, and substantial Rutherford-class improvement, but the absence of an active comparator means the result should not be converted into a blanket preference for all lesions. SUPERB trial Garcia 2015

Longer or more complex disease should prompt the operator to think beyond acute luminal gain. In a prospective multicenter Jetstream atherectomy extension of complex infrainguinal lesions, primary patency declined from 84.1% at 1 year to 58.5% at 5 years, and lesion complexity was the main predictor of long-term success. Three-year outcomes prospective 2026 The teaching point is not that atherectomy is mandatory, but that complex femoropopliteal disease fails over time in ways that require realistic consent, surveillance planning, and readiness for reintervention.

37.2CLTI changes the comparison

Chronic limb-threatening ischemia is not severe claudication; it is a different clinical state with different endpoints. The Global Vascular Guidelines organize CLTI revascularization around PLAN: patient risk, limb severity, and anatomic complexity. GVG 2019 WIfI is used to grade limb threat, and GLASS stages the target arterial path for infrainguinal disease, but GLASS requires angiographic assessment and should not be inferred from symptoms alone.

In CLTI, the femoropopliteal decision is not simply “endovascular versus bypass”; it is “which strategy gives this patient the best chance of limb salvage with acceptable risk and a usable target arterial path.” BEST-CLI provides the most important modern surgical lesson: among CLTI patients with adequate single-segment great saphenous vein, bypass-first therapy reduced major adverse limb event or death compared with endovascular-first therapy, whereas patients without adequate great saphenous vein did not show a statistically significant difference between strategies. BEST-CLI · 2022

The availability of good vein therefore changes the treatment conversation. When adequate single-segment great saphenous vein is present and the limb threat and anatomy justify durable reconstruction, bypass should remain a central option rather than a fallback after repeated failed endovascular attempts. When adequate vein is absent, the evidence is less decisive, and the surgeon must integrate patient risk, target path, conduit quality, and the consequences of failure without overextending conclusions from the smaller non-vein cohort. GVG 2019 · BEST-CLI · 2022

Historical and contemporary trials should be read in their anatomic context. BASIL randomized patients with severe limb ischemia from infrainguinal disease to surgery-first or angioplasty-first strategies and found similar amputation-free survival, with higher first-year hospital costs for surgery-first; however, it predates current drug-device technology and modern CLTI definitions. BASIL trial Bradbury 2005 BASIL-2, focused on patients requiring infrapopliteal revascularization, found better major amputation-or-death outcomes with an endovascular-first strategy than with vein-bypass-first therapy, but its below-trifurcation anatomy and trial setting differ from BEST-CLI. BASIL-2 Bradbury et 2023

For the femoropopliteal surgeon, the practical synthesis is disciplined selection. A CLTI patient with suitable vein, acceptable operative risk, and anatomy requiring durable inline flow may be best served by bypass-first planning. A patient with high procedural risk, no suitable vein, or anatomy more aligned with endovascular reconstruction may be better approached endovascularly. Neither strategy should be chosen because it is familiar; it should be chosen because PLAN, WIfI, GLASS, conduit assessment, and patient risk point in the same direction. GVG 2019 · BASIL-2 Bradbury et 2023 · BEST-CLI · 2022

37.3Drug-device evidence is bounded

Drug-coated and drug-eluting technologies have improved femoropopliteal patency in selected trial populations, but they do not eliminate the need for patient selection. IN.PACT SFA showed substantially better 12-month primary patency and much lower clinically driven target-lesion revascularization with paclitaxel-coated balloon angioplasty than with standard angioplasty in symptomatic superficial femoral and popliteal disease. IN.PACT SFA Tepe 2015 LEVANT 2 also showed higher 12-month primary patency with a paclitaxel-coated balloon than with standard balloon angioplasty, although target-lesion revascularization was not significantly different. LEVANT 2 2015

Drug-eluting stent data similarly support efficacy in selected femoropopliteal disease while requiring careful interpretation. At 5 years, Zilver PTX maintained superiority over standard endovascular therapy for clinical benefit, patency, and freedom from target-lesion revascularization, with an approximately 40% relative risk reduction for restenosis through 5 years. Zilver PTX year 2016 Crossovers and paclitaxel exposure within comparator pathways temper simple device-versus-device conclusions, so this evidence is best used to support the concept of durable antiproliferative benefit rather than indiscriminate stent placement.

The paclitaxel safety controversy must be presented openly during decision-making. A 2018 meta-analysis reported a late mortality signal after femoropopliteal paclitaxel-coated balloons or stents, including higher crude all-cause death through 5 years, which triggered major regulatory and academic scrutiny. Risk Death Following 2018 Later updated analysis incorporating more randomized data found no significant increase in all-cause mortality or major amputation at 1, 2, or 5 years, while confirming that patency and target-lesion-revascularization benefits were strongest through mid-term follow-up and attenuated by 5 years. Safety paclitaxel-coated devices 2026

This means consent should neither exaggerate nor dismiss the issue. The surgeon can explain that paclitaxel devices demonstrated patency advantages in femoropopliteal disease, that an earlier pooled analysis raised concern about late mortality, and that later pooled randomized evidence did not confirm a significant mortality or major-amputation excess. Safety paclitaxel-coated devices 2026 · Risk Death Following 2018 Device choice should remain individualized, and long-term surveillance remains appropriate because efficacy may diminish over time and the safety literature has evolved.

Real-world and niche-device data are useful for technical judgment but should not outrank randomized evidence. A single-center real-world cohort found restenosis varied by territory and device class, with different lowest-restenosis devices in iliac, superficial femoral, and popliteal segments; this supports the principle that femoropopliteal treatment should be territory-specific, but its retrospective single-center design prevents definitive ranking. Territory- Lesion-Specific Endovascular 2026 Similarly, case-level observations about scoring-balloon behavior and small technique series on embolic protection can sharpen awareness of failure modes without establishing standard-of-care superiority. Novel technique preventing 2026 · Case Scoring Site 2026

37.4Clinical integration, follow-up, and evidence boundaries

Good femoropopliteal practice integrates indication, anatomy, conduit, device evidence, and follow-up from the first consultation. In claudication, intervention follows inadequate response to medical therapy and structured exercise; in CLTI, the pathway begins with objective PAD, limb-threat staging, patient-risk assessment, and anatomic target-path planning. These two entry points should not be blurred, because a treatment that is reasonable for threatened tissue may be excessive for stable lifestyle-limiting symptoms. ACC/AHA 2024 · GVG 2019

The preprocedural conversation should make the expected failure mode explicit. Short femoropopliteal lesions may be reasonable endovascular targets; longer lesions may favor bypass when suitable vein and patient factors support surgery. Complex endovascular lesions can achieve high technical success yet lose patency over years, and single-arm or registry results should be used to frame expectations rather than to promise durability. ESC 2017 · Three-year outcomes prospective 2026

Follow-up should be aligned with what was done and why. A claudicant treated to improve function needs assessment of sustained walking benefit and recurrence that would justify reintervention. A CLTI patient needs surveillance focused on preservation of limb salvage strategy, because loss of patency may threaten tissue rather than simply reproduce exertional symptoms. Trial endpoints such as primary patency, target-lesion revascularization, major adverse limb event, amputation-free survival, and death should be translated into patient-specific follow-up goals rather than treated as interchangeable measures. BEST-CLI · 2022 · SVS Reporting Endo 2016

Reintervention should be purposeful. Restenosis after a femoropopliteal intervention is not automatically an indication for another procedure; the decision depends on symptoms, limb threat, anatomy, prior treatment, and remaining durable options. In CLTI, repeated endovascular failure can consume time and targets; in claudication, repeated treatment may expose the patient to escalating procedural risk for a non-limb-threatening problem. ACC/AHA 2024 · BEST-CLI · 2022

The central evidence boundary is that much of the device literature is lesion- and population-specific. Paclitaxel-coated balloons, paclitaxel-eluting stents, interwoven nitinol stents, atherectomy platforms, scoring balloons, and embolic-protection techniques each have data that apply to particular patients, lesion types, and study designs. Novel technique preventing 2026 A senior trainee should learn to ask three questions before adopting a device-based conclusion: Was the studied population like this patient? Was the treated anatomy like this lesion? Was the endpoint clinically meaningful for this limb problem? Zilver PTX year 2016 · IN.PACT SFA Tepe 2015 · SUPERB trial Garcia 2015